Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis

The Lancet Respiratory Medicine

Volumn 4, Issue 9, 2016, Pages 731-741

  Pavord, Ian D ^a   Lettis, Sally ^b   Anzueto, Antonio ^c   Barnes, Neil ^b,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; VILANTEROL; BRONCHODILATING AGENT;

ADULT; ARTICLE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; AGED; BLOOD; COMPLICATION; EOSINOPHIL; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; LOEFFLER PNEUMONIA; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EOSINOPHILIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84989816140     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30148-5     Document Type: Article

References (34)

1. 1 Jiang, HL, Chen, HX, Liu, W, Fan, T, Liu, GJ, Mao, B, Is COPD associated with increased mortality and morbidity in hospitalized pneumonia? A systematic review and meta-analysis. Respirology 20 (2015), 1046–1054.
2. 2 Cillóniz, C, Polverino, E, Ewig, S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 144 (2013), 999–1007.
3. 3 Restrepo, MI, Mortensen, EM, Pugh, JA, Anzueto, A, COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 28 (2006), 346–351.
4. 4 Crim, C, Dransfield, MT, Bourbeau, J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 12 (2015), 27–34.
5. 5 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html, 2015 (accessed July 30, 2015).
6. 6 Dransfield, MT, Bourbeau, J, Jones, PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 1 (2013), 210–223.
7. 7 Crim, C, Calverley, PMA, Anderson, JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34 (2009), 641–647.
8. 8 Kew, KM, Seniukovich, A, Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3, 2014 CD010115.
9. 9 Liapikou, A, Toumbis, M, Torres, A, Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia. Expert Opin Drug Saf 14 (2015), 1237–1247.
10. 10 Wedzicha, JA, Calverley, PMA, Seemungal, TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177 (2008), 19–26.
11. 11 Pascoe, S, Locantore, N, Dransfield, MT, Barnes, NC, Pavord, ID, Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3 (2015), 435–442.
12. 12 Siddiqui, SH, Guasconi, A, Vestbo, J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192 (2015), 523–525.
13. 13 Pavord, ID, Lettis, S, Locantore, N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax 71 (2016), 118–125.
14. 14 Bafadhel, M, McKenna, S, Terry, S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 186 (2012), 48–55.
15. 15 Shaaban, H, Daniel, S, Sison, R, Slim, J, Perez, G, Eosinopenia: is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital?. J Crit Care 25 (2010), 570–575.
16. 16 Bafadhel, M, Davies, L, Calverley, PM, Aaron, SD, Brightling, CE, Pavord, ID, Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 44 (2014), 789–791.
17. 1 and symptoms in COPD patients following 24 weeks of twice-daily treatment with salmeterol 50/fluticasone propionate 500 combination. Am J Respir Crit Care Med, 163, 2001, A279.
18. 18 Mahler, DA, Wire, P, Horstman, D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002), 1084–1091.
19. 19 Kerwin, EM, Scott-Wilson, C, Sanford, L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med 107 (2013), 560–569.
20. 20 Martinez, FJ, Boscia, J, Feldman, G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med 107 (2013), 550–559.
21. 21 GlaxoSmithKline. Clinical Study Report SCO30002. http://www.gsk-clinicalstudyregister.com/files2/gsk-sco30002-clinical-study-report-redact-v02.pdf (accessed May 10, 2016).
22. 22 GlaxoSmithKline. Clinical Study Report SFCA3007. http://www.gsk-clinicalstudyregister.com/files2/sfca3007-clinical-study-report-redact-v02.pdf (accessed May 10, 2016).
23. 23 GlaxoSmithKline. Clinical Study Report SCO100470. http://www.gsk-clinicalstudyregister.com/files2/gsk-sco100470-clinical-study-report-redact-v02.pdf (accessed May 10, 2016).
24. 24 GlaxoSmithKline. Clinical Study Report SFCB3024. http://www.gsk-clinicalstudyregister.com/files2/sfcb3024-clinical-study-report-redact-v02.pdf (accessed May 10, 2016).
25. 25 Celli, BR, MacNee, W, Agusti, A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004), 932–946.
26. 26 Wedzicha, JA, Banerji, D, Chapman, KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med, 2016, 10.1056/NEJMoa1516385 published May 15.
27. 27 Young, B, Lowe, JS, Stevens, A, Heath, JW, Wheater's Functional Histology, 5th edn., 2006, Elsevier, Philadelphia, PA.
28. 28 Blanchard, C, Rothenberg, ME, Biology of the eosinophil. Adv Immunol 101 (2009), 81–121.
29. 29 Yousefi, S, Gold, JA, Andina, N, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med 14 (2008), 949–953.
30. 30 Bafadhel, M, McKenna, S, Terry, S, et al. Acute exacerbations of COPD: identification of biological clusters and their biomarkers. Am J Respir Crit Care Med 184 (2011), 662–671.
31. 31 Groenke, L, Disse, B, Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?. Lancet Respir Med, 3, 2015, e26.
32. 32 Steer, J, Gibson, J, Bourke, SC, The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 67 (2012), 970–976.
33. 33 Assaad, U, El-Masri, I, Porhomayon, J, El-Solh, AA, Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging 7 (2012), 453–461.
34. 34 Landis, S, Suruki, R, Galwey, N, LATE-BREAKING ABSTRACT: Stability of blood eosinophil count in COPD patients in the UK clinical practice research datalink. Eur Respir J, 46, 2015, PA4047.